Dawex Data Exchange Technology Interfaces with Data Connectors to Power Data Spaces
8.11.2023 17:10:00 CET | Business Wire | Press Release
Dawex, the leader in Data Exchange solutions, today announced that Dawex Data Exchange technology interfaces with data connectors to support orchestrators in the deployment of data spaces and data intermediaries. With Dawex Data Exchange Platform solutions, orchestrators can enroll, operate, boost and monitor their data spaces, either managed or decentralized, by leveraging the deployment of data connectors, such as EDC connectors implementing the IDSA specification, according to the de facto Gaia-X standard and in compliance with the Data Governance Act.
Thanks to the deployment of multi-data connectors, Dawex technology delivers true interoperability with any data infrastructure that may be used by data providers and data acquirers. By interfacing with a wide range of connectors agnostic to the infrastructure or application layers, Dawex Data Exchange Platform solutions allow to manage Data Exchanges in a distributed approach and build data spaces & data intermediaries easily, connecting Data Fabrics and infrastructures from different vendors.
Dawex Data Exchange Platform solutions deliver all necessary capabilities to natively respond to business and technical challenges that arise when exchanging data at scale such as: trust in data transactions, compliance with regulations, security and privacy requirements, flexibility of the business modeling and of the governance models, performance and interoperability of the solutions. Dawex Data Exchange technology addresses the needs of the orchestrator operating the platform as a trusted intermediary, as well as the needs of the data providers and data acquirers engaged in trusted data transactions.
Today, organizations from multiple sectors, as well as European data spaces such as TEMS, the trusted European Media data space, and SM4RTENANCE, the European data space for Manufacturing, and the Gaia-X lighthouse project Agdatahub, the data intermediation platform for agriculture & agrifood, rely on the most complete and efficient Data Exchange solution powered by Dawex technology, to securely distribute or share data products, with trust, in compliance with data regulations.
Thanks to Dawex technology, organizations benefit from a wide range of features & capabilities to facilitate data circulation, scale operations in any business model and ultimately boost & accelerate the deployment of their data spaces and data intermediaries.
“Today’s organizations are seeking to improve their operations, foster innovation, capitalize on the potential of their data, or more generally take an ecosystemic leadership in an increasingly interconnected economy.” says Laurent Lafaye, co-CEO at Dawex. “Dawex Data Exchange Platform solutions are designed so orchestrators can rely on open, secure, compliant and trustworthy technology, delivering industrialized & future proof Data Exchanges.”
About Dawex
Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, for any business case, in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems and data spaces such as Corporate Data Hubs, Industry Data Hubs and Data Marketplaces to address economic, environmental and decarbonation challenges. At the invitation of the United Nations, Dawex joins the Data expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108582593/en/
Contact information
Press:
Isabelle Joulot
Vice President Communications & Marketing
press@dawex.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom